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Background: Previous studies have found an outstanding role in the regulation of metabolism of clear cell renal cell carcinoma (ccRCC; Gatto et al., 2014; Creighton et al.,
2013). We discovered that glycosaminoglycan (GAG) biosynthesis was prominently regulated in ccRCC, and measurements of circulating GAGs could be condensed into
scores that distinguished metastatic ccRCC with accuracy ranging 92.7% to 100% (Gatto et al., 2016). However, it is still unknown if GAG scores could detect cancer at
earlier stages and across other histologies. 
Methods and Results: We measured plasma GAGs in pre-operative samples from a retrospective consecutive series of 218 patients with a radiographic finding of renal
mass. A control group was formed with 19 healthy volunteers and 25 historical healthy samples. In clustering analyses, plasma GAGs distinguished the 179 RCC samples
as a separate group in an unbiased fashion. The previous GAG score was updated and achieved an area-under-the-curve (AUC) equal to 0.994 (95% CI: 0.985 - 1) in the
validation set with a sensitivity of 95.7%. The GAG score was not significantly associated with age or gender nor with any histopathologic features. 
Conclusions: Plasma GAG scores are specifically altered in RCC patients and can detect the disease irrespective of stage and histology with elevated accuracy.
Abstract
Methods
We measured GAG profiles in pre-
operative plasma samples versus healthy 
controls with the aim to characterize 
GAG scores for the detection of early 
stage RCC.
The study was retrospective and double-
blinded. Inclusion criteria were: patients 
with radiographic finding of a renal mass; 
healthy volunteers without any history of 
malignancy. Exclusion criteria were: no 
records on date of surgery; a pre-
operative sample was obtained 50 days 
or earlier with respect to the date of 
surgery; absence of pre-operative 
samples following filtering out outliers or 
laboratory assay failures. Participants 
were enrolled at Memorial Sloan 
Kettering Cancer Center, New York City, 
United States between May 2011 and 
February 2014. Eligible participants  
formed a consecutive series. 
Laboratory measurements of the GAG 
profile quantified 19 properties using 
capillary electrophoresis with laser 
induced fluorescence, as previously 
described (Volpi and Lindhardt, 2010).
Study population
In total, 237 subjects were retrospectively enrolled
in this study, 218 patients and 19 healthy
volunteers as controls. Following eligibility, 194
patients with pre-op samples were included in this
study.
 
The median age at diagnosis was 60 years (IQR:
52-67, Table 1). The most common pathologic
diagnosis was RCC (N=162 patients, 90%),
followed by oncocytoma (N=7, 4%) and
angiomyolipoma (N=6, 3%). The median age at
diagnosis in the healthy cohort was 55 years (IQR:
50-60), and included 6 males and 13 females.
Limited to the sub-cohort of 162 RCC cases, the
demographic characteristics were similar to the
patient cohort (Table 2). The most common
histological subtype was ccRCC (N=113, 70%). Of
the remaining 49 non-ccRCC, the most common
histological subtype was papillary RCC (pRCC, N
=25), followed by chromophobe RCC (chRCC, N
=17). Most RCC cases were localized (pT1, N =86
[53%]), with the vast majority below 4 cm in size
(pT1a, N = 66). The remaining RCC cases were
predominantly locally-advanced (Stage II or III, N =
66). Finally, there were 12 cases of advanced
disease (pM1, N =11 and pT4, N =1).
Table 1 Table 2
Clustering analysis reveals plasma GAG alterations across RCC stages and histologies
We performed a principal component analysis (PCA) to ascertain in an unbiased fashion how similar the overall GAG profiles were 
across pre-operative RCC and healthy volunteers’ samples (Figure 1A). The PCA plot evidenced that samples obtained from RCC 
patients pre-operatively tended to cluster as a separate group with limited overlap with those obtained from healthy volunteers.
We used unsupervised hierarchical clustering based on the between-sample GAG profile correlation to validate the PCA results and 
to highlight the GAGs that contributed most to the separation of RCC from healthy subjects (Figure 1B). Five properties were 
noticeably altered in RCC va. healthy both in this cohort and in historical cohorts (Figure 2).
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Figure 2
GAG scores detected any stage RCC with 95.7% sensitivity
We sought to redefine the GAG scores in 
order to incorporate GAG property alterations 
observed in the current cohort as well as 
those observed in historical cohorts.
The new plasma GAG score achieved an 
AUC equal to 0.999, with 98.8% accuracy, 
94.7% specificity and 100% sensitivity at an 
optimal cut-off equal to 0.87 (Figure 3). The 
new GAG score was elevated in all RCC 
samples, irrespective of stage and histology. 
The new GAG score performed similarly in 
our historical cohorts, with AUC = 1 in the 
Italian cohort (N=28) and 0.988 in the 
Swedish cohort (N=46, Figure 4).
The new GAG score achieved an AUC equal 
to 0.994 (95% CI: 0.985 - 1) in the validation 
set. At the pre-specified cut-off, the validated 
sensitivity was 95.7% (Figure 3).
The new GAG score did not correlate with 
age, gender, nor histopathologic features. 
However, two of its constituent GAG 
properties showed a weak correlation with 
tumor stage, size and/or histology (Figure 5).
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Conclusions
Plasma GAGs defined a 
specific signature in RCC 
patients vs. healthy 
subjects (N=179). By 
updating the definition of 
GAG scores, it was 
possible to detect RCC 
irrespective of its stage or 
histology with 95.7% 
sensitivity in an 
independent validation set. 
The lack of correlation with 
pathologic features 
suggests that the process 
beyond the GAGs’ 
alterations is triggered 
concomitantly with tumor 
formation but independent 
of its progression. 
This large scale 
retrospective study 
warrants prospective trials 
to validate the clinical utility 
of multiple applications for 
GAG scores as diagnostic 
biomarkers in RCC.
